Krsnaa Diagnostics secures 15-year Punjab PET-CT concession deal
- Krsnaa Diagnostics signed a 15-year concession agreement for PET-CT facilities in Punjab
- The deal involves four government hospitals under a DBFOT public-private partnership model
- Revenue will be cash-based, dependent on scan volumes and user charges rather than fixed fees
- This marks the company's first entry into the PET-CT diagnostic segment

*this image is generated using AI for illustrative purposes only.
Krsnaa Diagnostics has executed a concession agreement with the Government of Punjab to develop and operate PET-CT diagnostic facilities. The deal covers four government hospitals under a public-private partnership model.
The company signed the agreement following a Letter of Award dated August 14, 2026, issued by the Department of Health & Family Welfare, acting through the Punjab Health Systems Corporation (PHSC). This marks Krsnaa Diagnostics' formal entry into the PET-CT segment, an area it had previously avoided.
Deal Structure
The project operates under a Design, Build, Finance, Operate, Maintain and Transfer (DBFOT) format. The concession period spans 15 years. Revenue will be generated on a cash-based model, dependent on the actual number of scans performed and applicable user charges.
| Particulars | Details |
|---|---|
| Awarding Entity | Dept of Health & Family Welfare, Govt of Punjab (via PHSC) |
| Project Scope | Development and operation of PET-CT facilities at 4 hospitals |
| Model | Public-Private Partnership (PPP) under DBFOT format |
| Duration | 15 years |
| Revenue Basis | Cash-based, linked to scan volume and user charges |
Strategic Context
Krsnaa Diagnostics stated that the decision to enter this segment follows a measured approach and growing demand for advanced oncology diagnostics. The company aims to leverage its established capabilities in government healthcare partnerships.
Management noted that the long-term concession framework provides revenue visibility. The deal diversifies the company's portfolio beyond its existing diagnostic services while strengthening its cash portfolio of government PPP partnerships across India.
What the Numbers Show
The absence of a fixed upfront consideration highlights the operational risk and reward structure of the deal. Unlike fixed-price contracts, Krsnaa's revenue is directly tied to patient volume and user charges. This structure aligns the company's earnings potential with the utilization rates of the new facilities over the 15-year term.
Historical Stock Returns for Krsnaa Diagnostics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.63% | -1.31% | -5.44% | -6.91% | -34.27% | 0.0% |
How will the variable revenue model based on scan volumes impact Krsnaa Diagnostics' earnings volatility compared to its existing fixed-fee diagnostic contracts?
What specific operational challenges might Krsnaa face in achieving high utilization rates for PET-CT scans in government hospitals during the initial years of the 15-year concession?
Could this entry into the PET-CT segment signal a broader strategic shift for Krsnaa towards high-margin oncology diagnostics, potentially influencing future M&A or expansion targets?
































